About This Treatment Guide

Article

About This Treatment Guide

The Oncology Group of CMPMedica, publisher of ONCOLOGY and Oncology NEWS International, and the website, cancernetwork.com, is pleased to present Cancer Management: A Multidisciplinary Approach, 11th edition. Cancer Management: A Multidisciplinary Approach is designed to present important clinical information concisely, uniformly, and logically, emphasizing the natural history of the malignancy, screening and diagnosis, staging and prognosis, and treatment.

The fundamental principle behind this comprehensive treatment guide is the importance of a truly integrated, multidisciplinary approach to the management of the patient with cancer. Accordingly, the discussion of each disease site combines the perspectives of medical oncology, surgical oncology, and radiation oncology, as appropriate. Further, each of the book’s medical editors represent a particular discipline.

The Oncology Group would like to thank the contributors and all involved in the development and production of this important handbook. In particular, we thank the book’s principal editors:

 

Richard Pazdur, MD

(Medical Oncology)
US Food and Drug Administration

Lawrence D. Wagman, MD

(Surgical Oncology)
Center for Cancer Prevention and Treatment, St. Joseph Hospital

Kevin A. Camphausen, MD

(Radiation Oncology)
National Cancer Institute

William J. Hoskins, MD

(Gynecologic Oncology)
Memorial Sloan-Kettering Cancer Center


We also thank the staff of The Oncology Group and in particular wish to recognize the efforts of Angela Cibuls and Susan Reckling.

This 11th edition has been produced in an effort to keep pace with the rapidly changing field of oncology. Be sure to visit www.cancernetwork.com, where the full text of this edition will be made available online, with important updates as appropriate.

Please let us know how you use this book, and how we can make it even more valuable. We look forward to hearing from you.

Sincerely,

Cara H. Glynn
Beth Scholz

 

 

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Panelists smiling at camera on a blue background.
Panelists smiling at camera on a blue background.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Related Content